Merck Announces Topline Results From The Pivotal Phase 2b/3 BRUNELLO Trial Of Remigromig In Adults With Diabetic Macular Edema

Merck (MRK) received an FDA label update for WINREVAIR in pulmonary arterial hypertension, including Phase 3 trial data. The stock has seen significant gains, with a 1-year total shareholder return of 91.32%. Merck's pipeline expansion and strategic moves aim to drive long-term earnings, though risks include Keytruda exclusivity loss and pricing pressures. The stock trades at $148.08, near its fair value estimate of $150.42, with a high P/E ratio of 115.1x.

Merck & Co Inc (MRK) reported positive Phase 2b/3 trial results for remigromig in diabetic macular edema, meeting primary endpoints. The stock is 22.6% overvalued per GF Value™, with a 2.29% dividend yield and a high payout ratio of 1.11, raising sustainability concerns. MRK has a GF Score™ of 76, indicating solid profitability and growth but moderate financial strength and low momentum.

Merck (MRK) reported that its drug remigromig met the primary endpoint in a Phase 2b/3 study for diabetic macular edema, showing non-inferiority to ranibizumab. Both doses of remigromig were well-tolerated but had higher adverse event rates. Merck plans to present results in 2026 and discuss with regulators. MRK stock is down 1.88% at close.

Merck (MRK) reported that its diabetic eye drug, remigromig, met noninferiority goals in the BRUNELLO trial against ranibizumab, but did not disclose detailed efficacy or safety data. The company plans to discuss findings with regulators. Shares closed at $148.08 before the announcement.

Merck's remigromig met its primary endpoint in a Phase 2b/3 trial for diabetic macular edema, showing non-inferiority to ranibizumab. Both doses were well tolerated, but adverse events were more frequent. Merck plans to discuss results with regulators and continues other trials. According to the company, additional safety analyses are underway.

Bio-Techne (TECH) shareholders approved its acquisition by Merck KGaA (MKKGY.PK). The deal is expected to close by early 2027, with TECH shares up 0.06% to $72.60. The acquisition aims to combine complementary life sciences organizations and deliver cash value to TECH shareholders.